21:32 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.1 million) on Jan. 4 in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU...
22:38 , Jan 4, 2018 |  BC Extra  |  Financial News

Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.2 million) in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for...
18:09 , Oct 20, 2017 |  BC Week In Review  |  Company News

Axxam and Sanofi to optimize CNS compounds

Axxam S.p.A. (Milan, Italy) said last month it partnered with Sanofi (Euronext:SAN; NYSE:SNY) to optimize lead small molecules, discovered by Axxam , in development to treat CNS diseases. Research will be performed at Sanofi and...
22:03 , Jan 6, 2017 |  BC Week In Review  |  Company News

Axxam, Acousia deal

Axxam transferred undisclosed assets to Acousia's R&D programs. Acousia is developing small molecules to treat sensorineural hearing loss and to prevent hearing loss in at-risk patients. Last month, Axxam participated in Acousia’s €2.5 million ($2.6...
17:18 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Acousia completes venture financing

Acousia raised €2.5 million ($2.6 million) in a venture round led by Boehringer Ingelheim Venture Fund. KfW and Axxam S.p.A. also participated. Acousia Therapeutics GmbH , Tübingen, Germany ...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Company News

Axxam, Gruenenthal deal

The companies partnered to discover and develop small molecules to treat pain and inflammation using Axxam’s early drug discovery platform with pathways and targets from Gruenenthal. The companies declined to disclose financial terms. Axxam S.p.A....
07:00 , May 11, 2015 |  BioCentury  |  Product Development

Check your effectors

Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence that targeting Kv1.3 channels may quell an active autoimmune response by halting activation of effector memory T cells while...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Axxam, Hit Discovery Constance, Lead Discovery Center, Centre for Drug Design and Discovery (CD3) supply/service, high throughput screening news

CRO Axxam, biotech Lead Discovery and the technology transfer platform and investment fund CD3 debuted their JV, Hit Discovery Constance GmbH, to provide drug discovery research services, including assay development and high throughput screening. The...
07:00 , Jun 6, 2013 |  BC Innovations  |  Targets & Mechanisms

Watching obesity on a new channel

Researchers at the University of California, Irvine , have found a potassium channel Kv1.3 inhibitor that may help treat obesity-related diseases. 1 The team had previously licensed one inhibitor, ShK-186 , to Kineta Inc. for...